Affimed N.V. (AFMDQ)
| Market Cap | 1.64K -98.0% |
| Revenue (ttm) | 6.29M -72.9% |
| Net Income | -78.04M |
| EPS | -5.07 |
| Shares Out | 16.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,400 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | n/a |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Affimed
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme... [Read more]
Financial Performance
In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.
Financial numbers in EUR Financial StatementsNews
Affimed receives Nasdaq delisting notice
Affimed (AFMD) announced that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department notifying the company that, in accordance with Nasdaq Listing Rule 5101,…
Affimed downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Affimed (AFMD) to Neutral from Buy without a price target after the company announced its decision to file an application for opening of insolvency proceedings with the…
Affimed downgraded to Equal Weight at Wells after insolvency filing
Wells Fargo downgraded Affimed (AFMD) to Equal Weight from Overweight with a price target of 10c, down from $11, following the announcement that the company is opening insolvency proceedings given…
Affimed downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Affimed (AFMD) to Equal Weight from Overweight with a price target of 10c, down from $11.
Affimed NV trading halted, news pending
08:25 EDT Affimed (AFMD) NV trading halted, news pending
Affimed announces filing for opeing of insolvency proceedings
Affimed (AFMD) announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed has been engaged in…
Affimed downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Affimed (AFMD) to Market Perform from Outperform with a price target of 39c, down from $5. The firm no longer believes it is likely the company will secure…
Affimed receives Nasdaq notice of non-compliance
Affimed (AFMD) announced that it has received a written notice dated April 15 from the Listing Qualifications Department of The Nasdaq Stock Market indicating that, for the last thirty consecutive…
Affimed Transcript: Leerink’s Global Healthcare Conference 2025
The session highlighted strong clinical progress for AFM24 and AFM28, with both programs showing promising efficacy and safety profiles in difficult-to-treat cancers. Strategic prioritization is ongoing, with investor and partner input guiding future development and financing decisions.
Affimed Slides: Corporate Presentation
Affimed has posted slides in relation to its latest quarterly earnings report, which was published on January 10, 2025.
Affimed price target lowered to $11 from $15 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Affimed (AFMD) to $11 from $15 and keeps an Overweight rating on the shares. The firm notes updated NSCLC…
Affimed price target lowered to $7 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Affimed (AFMD) to $7 from $10 and keeps a Buy rating on the shares. The firm delayed the projected U.S. launch of…
Affimed Transcript: Study Update
AFM24 plus atezolizumab showed robust efficacy and safety in heavily pretreated NSCLC, with higher drug exposure linked to improved outcomes. A new 720 mg cohort will open in 2025 to confirm enhanced response rates and PFS, supporting further clinical development.
Affimed Press release: Study Update
Affimed issued a press release on December 17, 2024, disclosing material business information to investors.
Affimed Slides: Study Update
Affimed has posted slides in relation to its latest quarterly earnings report, which was published on December 17, 2024.
Affimed’s AFM24/atezolizumab combination shows positive results in NSCLC trial
Affimed (AFMD) announced updated clinical data from the ongoing AFM24-102 trial of AFM24/atezolizumab combination therapy in heavily pretreated NSCLC patients. Results continue to demonstrate meaningf...
Affimed price target lowered to $15 from $20 at Wells Fargo
Wells Fargo lowered the firm’s price target on Affimed (AFMD) to $15 from $20 and keeps an Overweight rating on the shares. The firm notes that r/r HL data for…
Affimed reports ‘promising’ Phase 1 efficacy, safety data for AFM28
Affimed (AFMD) N.V. announced the oral presentation of data on AFM28 at the 66th ASH Annual Meeting and Exposition. The data, derived from the first-in-human Phase 1 study of AFM28,…
Affimed: Acimtamig, AlloNK combination granted RMAT designation by FDA
Affimed (AFMD) announced that the U.S. FDA has granted RMAT designation to the combination therapy of Affimed’s innate cell engager acimtamig and Artiva Biotherapeutic’s (ARTV) AlloNK for the treatmen...
Affimed price target lowered to $4 from $5 at Stifel
Stifel lowered the firm’s price target on Affimed (AFMD) to $4 from $5 and keeps a Hold rating on the shares after the company provided granularity on the timing and…
Affimed Earnings Call Transcript: Q3 2024
Clinical programs for AFM24, AFM28, and acimtamig advanced, with key data updates at ASH 2024 and a December call for AFM24. Cash runway extends into Q4 2025, with reduced expenses and net loss. Strategic focus includes broadening partnerships and financial stability.
Affimed Earnings release: Q3 2024
Affimed released its Q3 2024 earnings on November 14, 2024, summarizing the period's financial results.
Affimed Slides: Q3 2024
Affimed has posted slides in relation to its Q3 2024 quarterly earnings report, which was published on November 14, 2024.
Affimed reports Q3 EPS *EUR0.94) vs. (EUR1.63) last year
Reports Q3 revenue EUR155K vs. EUR1.96M last year. “Our innate cell engager therapies are meeting the critical needs of cancer patients who often come to us after exhausting nearly all…